Medtronic Back to Normal Growth in China, CEO Says

The transcript discusses Medtronic's global business recovery post-COVID, highlighting growth in regions like China, the US, and Europe. It addresses the backlog of elective procedures and the timeline for recovery. Challenges in providing financial guidance due to COVID-19 uncertainties are noted. The transcript also covers Medtronic's product pipeline, including innovations in cardiac rhythm, neuro modulation, and robotic surgery, as well as a breakthrough hypertension therapy.

What is the current growth trend for Medtronic in China?

• Robust double-digit growth

• Declining growth

• Stagnant growth

• Negative growth

What is a key indicator of recovery in the United States according to Medtronic?

• Decrease in hospital admissions

• Increase in elective procedure equipment purchases

• Reduction in COVID-19 cases

• Increase in pharmaceutical sales

How long did it take Medtronic to work through the backlog from the first wave of COVID?

• Six to seven months

• Nine months

• Three months

• One year

What is the anticipated timeline for Medtronic to work through the current backlog of elective procedures?

• One year

• Nine months

• Six months

• Three months

What is one reason Medtronic has not provided financial guidance?

• Regulatory issues

• Insufficient data on sales

• Uncertainty due to COVID-19 variants

• Lack of demand for products

Which business area of Medtronic is experiencing significant growth?

• Cardiac rhythm management

• Orthopedic devices

• Diagnostic equipment

• Pharmaceuticals

What is the expected impact of Medtronic's new hypertension therapy?

• No significant change

• Meaningful reduction in blood pressure

• Increase in blood pressure

• Increase in stroke risk